Syncona chief investment officer Chris Hollowood (Syncona)
November 19, 2020 10:23 AM ESTUpdated 10:35 AM
Financing

Syn­cona launch­es new gene ther­a­py play­er Pure­spring, spun out of the Uni­ver­si­ty of Bris­tol, with a rough­ly $60M Se­ries A

Max Gelman

Senior Editor

Long­time UK life sci­ences in­vestor Syn­cona has a new gene ther­a­py out­fit, one that the firm says is one of the first ever to fo­cus …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Sen­ate Ju­di­cia­ry Com­mit­tee ad­vances patent bill with new pro­tec­tions for phar­ma chal­lenges

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

A service from the Financial Times